AI Access Brief Podcast

Episode 20 — 17 July 2026

Examining CMS CAR-T coverage implications, FDA's RWE guidance for accelerated approvals, ISPOR's value pricing pivot, and NICE's ultra-rare disease framework updates.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 61 — 16 July 2026

Navigating EU HTA regulation teething problems, CMS Part D redesign implementation barriers, RWE utility in accelerated approvals, and gene therapy cost-effectiveness thresholds in high-income markets.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 60 — 15 July 2026

Examining CMS Part D redesign, ICER's Alzheimer's report, EMA's rare disease pathway, and FDA's Breakthrough expansion.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 59 — 15 July 2026

FDA approves first KRAS inhibitor in NSCLC; EMA recommends SMA gene therapy; NICE proposes £50k QALY threshold; JCA faces 40% request surge.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 58 — 15 July 2026

HCA's profit warning signals US healthcare access pressures; SubQ Leqembi's approval reshapes Alzheimer's HEOR; FTC insulin pricing settlement impacts formulary dynamics; ICER expands scientific advice amid evidence gaps.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 57 — 15 July 2026

This episode examines US pricing pressures on PBMs and discount programs, the growing importance of biomarker-driven therapies in HEOR strategies, and how M&A is accelerating differentiated drug development.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 56 — 14 July 2026

This episode examines how US healthcare system strain impacts drug reimbursement, the HEOR implications of administration innovations like subQ Leqembi, and the evolving competitive landscape in oncology and psoriasis treatments.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 56 — 14 July 2026

FDA grants Trodelvy accelerated approval with RWE conditions, CMS implements Part D step therapy, NICE reverses Orkambi rejection using RWE, and EU launches JCA for AI diagnostics.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 55 — 14 July 2026

Examining emerging challenges in evidence generation and evaluation, from AI in HTA to RWE in emerging markets, as healthcare systems adapt to new realities.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast

Episode 54 — 13 July 2026

Examining emerging HTA frameworks in the GCC, Brazil's pricing shifts, Africa's RWE adoption, Australia's digital health challenges, and Japan's gene therapy evidence strategies.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast